SiBone (NASDAQ:SIBN) SVP Sells $17,168.10 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 1,335 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $12.86, for a total transaction of $17,168.10. Following the completion of the transaction, the senior vice president directly owned 282,840 shares in the company, valued at approximately $3,637,322.40. This represents a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

SiBone Stock Performance

SIBN opened at $13.12 on Monday. SiBone has a twelve month low of $12.15 and a twelve month high of $21.89. The firm has a market capitalization of $579.51 million, a PE ratio of -29.82 and a beta of 0.77. The company has a current ratio of 8.55, a quick ratio of 7.21 and a debt-to-equity ratio of 0.20. The firm’s 50-day moving average price is $14.62 and its 200 day moving average price is $16.39.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. SiBone had a negative net margin of 9.41% and a negative return on equity of 11.01%. The company had revenue of $56.35 million during the quarter, compared to the consensus estimate of $56.26 million. As a group, sell-side analysts expect that SiBone will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of SiBone during the 1st quarter worth about $225,000. Goldman Sachs Group Inc. raised its holdings in SiBone by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after buying an additional 83,919 shares during the period. Jane Street Group LLC purchased a new stake in SiBone in the 1st quarter valued at about $1,818,000. Finally, Legal & General Group Plc raised its holdings in SiBone by 16.1% in the 2nd quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock valued at $798,000 after buying an additional 5,888 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Needham & Company LLC lifted their price target on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. TD Cowen boosted their price target on shares of SiBone from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Finally, Truist Financial reissued a “buy” rating and issued a $24.00 price objective (up from $23.00) on shares of SiBone in a report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.